首页>Pharmacoepidemiology and drug safety>Cardiovascular and mortality risk in elderly Medicare beneficiaries treated with olmesartan versus other angiotensin receptor blockers
Cardiovascular and mortality risk in elderly Medicare beneficiaries treated with olmesartan versus other angiotensin receptor blockers
作者单位：Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, United[1]Acumen, LLC, Burlingame, CA, United States, Stanford University, Palo Alto, CA, United States[2]Centers for Medicare and Medicaid Services, Washington, DC, United States[3]Acumen, LLC, Burlingame, CA, United States[4]
换一批
